Unknown

Dataset Information

0

Amongst Women Stratified to Receive Endocrine Therapy on the Basis of Their Tumor Estrogen and Progesterone Receptor Levels, Those with Higher Tumor Progesterone Receptor Levels Had a Better Outcome Than Those with Lower Levels of Tumor Progesterone Receptor.


ABSTRACT:

Background

To realize the association between stratified expression levels of ER and PgR and long-term prognosis of breast cancer patients who received adjuvant hormone therapy, this study aimed to propose better prognostic cut-off levels for estrogen receptor (ER) and progesterone receptor (PgR).

Methods

Patients who received adjuvant hormone therapy after surgical intervention were selected. The ER and PgR status and their effects on breast cancer-specific survival (BCSS) and disease-free survival (DFS) over 5 and 10 years were evaluated. Next, subgroups were generated based on ER and PgR expression percentage and Allred scores. Survival curves were constructed using the Kaplan-Meier method.

Results

ER and PgR expression were significantly associated with better prognosis in 5 years, whereas only PgR expression was significantly associated during the 10-year follow-up. The optimal cut-off values for better 5-year BCSS were ER > 50%; ER Allred score > 7; PgR ? 1%; or PgR Allred score ? 3; the corresponding values for DFS were ER > 40%; ER Allred score > 6; PgR > 10%; or PgR Allred score ? 3. In the long-term follow-up, PgR of > 50% or Allred score of > 5 carriers revealed a better prognosis of both BCSS and DFS.

Conclusion

Patients with a PgR expression > 50% or an Allred score > 5 exhibited better 10-year BCSS and DFS.

SUBMITTER: Lin TH 

PROVIDER: S-EPMC7926358 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Amongst Women Stratified to Receive Endocrine Therapy on the Basis of Their Tumor Estrogen and Progesterone Receptor Levels, Those with Higher Tumor Progesterone Receptor Levels Had a Better Outcome Than Those with Lower Levels of Tumor Progesterone Receptor.

Lin Tai-Han TH   Gao Hong-Wei HW   Liao Guo-Shiou GS   Yu Jyh-Cherng JC   Dai Ming-Shen MS   Ho Jar-Yi JY   Yu Cheng-Ping CP  

Cancers 20210221 4


<h4>Background</h4>To realize the association between stratified expression levels of ER and PgR and long-term prognosis of breast cancer patients who received adjuvant hormone therapy, this study aimed to propose better prognostic cut-off levels for estrogen receptor (ER) and progesterone receptor (PgR).<h4>Methods</h4>Patients who received adjuvant hormone therapy after surgical intervention were selected. The ER and PgR status and their effects on breast cancer-specific survival (BCSS) and di  ...[more]

Similar Datasets

| S-EPMC4432400 | biostudies-literature
| S-EPMC4595063 | biostudies-literature
| S-EPMC7782753 | biostudies-literature
| S-EPMC6299689 | biostudies-literature
| S-EPMC7785602 | biostudies-literature
| S-EPMC170950 | biostudies-literature
| S-EPMC5056466 | biostudies-literature
| S-EPMC1868040 | biostudies-literature
| S-EPMC7475037 | biostudies-literature
| S-EPMC2442700 | biostudies-literature